Brandon Couillard
Stock Analyst at Wells Fargo
(4.22)
# 463
Out of 4,981 analysts
142
Total ratings
56.04%
Success rate
13.85%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Overweight | $135 → $140 | $123.24 | +13.60% | 23 | Aug 28, 2025 | |
| CDNA CareDx | Maintains: Equal-Weight | $19 → $14 | $13.53 | +3.47% | 3 | Aug 8, 2025 | |
| MLAB Mesa Laboratories | Upgrades: Equal-Weight | $100 → $67 | $61.57 | +8.82% | 3 | Aug 8, 2025 | |
| WAT Waters | Maintains: Equal-Weight | $330 → $315 | $295.39 | +6.64% | 5 | Aug 5, 2025 | |
| BRKR Bruker | Maintains: Overweight | $60 → $50 | $30.91 | +61.76% | 5 | Aug 5, 2025 | |
| AVTR Avantor | Maintains: Overweight | $19 → $16 | $12.31 | +29.98% | 5 | Aug 4, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Equal-Weight | $245 → $265 | $280.34 | -5.47% | 12 | Aug 1, 2025 | |
| BIO.B Bio-Rad Laboratories | Maintains: Equal-Weight | $245 → $265 | $279.70 | -5.26% | 12 | Aug 1, 2025 | |
| RGEN Repligen | Maintains: Overweight | $180 → $175 | $113.54 | +54.13% | 2 | Jul 30, 2025 | |
| WGS GeneDx Holdings | Maintains: Equal-Weight | $78 → $95 | $123.95 | -23.36% | 4 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $570 → $565 | $479.46 | +17.84% | 6 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $210 → $205 | $190.05 | +7.87% | 3 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59 | $51.26 | +15.10% | 1 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $6 | $7.24 | -17.13% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,125 → $1,200 | $1,259.54 | -4.73% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $130 → $102 | $82.87 | +23.08% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $131.56 | +97.63% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $69.01 | +15.93% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $85 | $53.94 | +57.58% | 16 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $2.65 | +277.36% | 1 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $21.01 | +9.47% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.72 | +1,703.80% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.31 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $2.43 | +352.67% | 2 | Oct 13, 2017 |
Agilent Technologies
Aug 28, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $123.24
Upside: +13.60%
CareDx
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $19 → $14
Current: $13.53
Upside: +3.47%
Mesa Laboratories
Aug 8, 2025
Upgrades: Equal-Weight
Price Target: $100 → $67
Current: $61.57
Upside: +8.82%
Waters
Aug 5, 2025
Maintains: Equal-Weight
Price Target: $330 → $315
Current: $295.39
Upside: +6.64%
Bruker
Aug 5, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $30.91
Upside: +61.76%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $12.31
Upside: +29.98%
Bio-Rad Laboratories
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $245 → $265
Current: $280.34
Upside: -5.47%
Bio-Rad Laboratories
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $245 → $265
Current: $279.70
Upside: -5.26%
Repligen
Jul 30, 2025
Maintains: Overweight
Price Target: $180 → $175
Current: $113.54
Upside: +54.13%
GeneDx Holdings
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $78 → $95
Current: $123.95
Upside: -23.36%
Jul 24, 2025
Maintains: Overweight
Price Target: $570 → $565
Current: $479.46
Upside: +17.84%
Jul 23, 2025
Maintains: Equal-Weight
Price Target: $210 → $205
Current: $190.05
Upside: +7.87%
May 30, 2025
Initiates: Overweight
Price Target: $59
Current: $51.26
Upside: +15.10%
May 8, 2025
Downgrades: Equal-Weight
Price Target: $22 → $6
Current: $7.24
Upside: -17.13%
May 5, 2025
Maintains: Equal-Weight
Price Target: $1,125 → $1,200
Current: $1,259.54
Upside: -4.73%
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $130 → $102
Current: $82.87
Upside: +23.08%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $131.56
Upside: +97.63%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $69.01
Upside: +15.93%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $85
Current: $53.94
Upside: +57.58%
Aug 27, 2024
Initiates: Overweight
Price Target: $10
Current: $2.65
Upside: +277.36%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $21.01
Upside: +9.47%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $0.72
Upside: +1,703.80%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.31
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $2.43
Upside: +352.67%